Targeted therapies in the treatment of lung cancerBUNN, Paul A; JOHNSON, David H.Seminars in oncology. 2002, Vol 29, Num 1, issn 0093-7754, 154 p., SUP4Serial Issue

Targeted therapies for the treatment of lung cancerHERBST, Roy S.Seminars in oncology. 2005, Vol 32, Num 6, issn 0093-7754, 46 p., SUP10Conference Proceedings

Targeting angiogenesis in lung cancerSANDIER, Alan B.Seminars in oncology. 2005, Vol 32, Num 6, pp 16-22, issn 0093-7754, 7 p., SUP10Conference Paper

Meaningful survival in lung cancer patientsRAMALINGAM, Sakkaraiappan; BELANI, Chandra P.Seminars in oncology. 2002, Vol 29, Num 1, pp 125-131, issn 0093-7754, SUP4Article

Determinants of response and resistance to cytotoxicsROSELL, Rafael; MONZO, Mariano; ALBEROLA, Vicente et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 110-118, issn 0093-7754, SUP4Article

Bisphosphonates in the treatment of bone metastasesFINLEY, Rebecca S.Seminars in oncology. 2002, Vol 29, Num 1, pp 132-138, issn 0093-7754, SUP4Article

Genetic and immunologic therapies for lung cancerSWISHER, Stephen G; ROTH, Jack A; CARBONE, David P et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 95-101, issn 0093-7754, SUP4Article

HER2/neu expression in malignant lung tumorsHIRSCH, Fred R; FRANKLIN, Wilbur A; VEVE, Robert et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 51-58, issn 0093-7754, SUP4Article

Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancerBONOMI, Philip.Seminars in oncology. 2002, Vol 29, Num 1, pp 78-86, issn 0093-7754, SUP4Article

Overview of rationale and clinical trials with signal transduction inhibitors in lung cancerARTEAGA, Carlos L; KHURI, Fadlo; KRYSTAL, Geoffrey et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 15-26, issn 0093-7754, SUP4Article

Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancerBUNN, Paul A; CHAN, Daniel C; ALILA, Hector et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 87-94, issn 0093-7754, SUP4Article

Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxiaGANDARA, David R; LARA, Primo N; GOLDBERG, Zelanna et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 102-109, issn 0093-7754, SUP4Article

New agents, new treatment, and antiemetic therapyGRALLA, Richard J.Seminars in oncology. 2002, Vol 29, Num 1, pp 119-124, issn 0093-7754, SUP4Article

Angiogenesis inhibitors in clinical development for lung cancerHERBST, Roy S; HIDALGO, Manuel; PIERSON, A. Scott et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 66-77, issn 0093-7754, SUP4Article

Other compounds and targets in non-small cell lung cancerVILLAFLOR, Victoria; BONOMI, Philip.Seminars in oncology. 2005, Vol 32, Num 6, pp 30-36, issn 0093-7754, 7 p., SUP10Conference Paper

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitorsLANGER, Corey J; NATALE, Ronald B.Seminars in oncology. 2005, Vol 32, Num 6, pp 23-29, issn 0093-7754, 7 p., SUP10Conference Paper

Epidermal growth factor receptor family in lung cancer and premalignancyFRANKLIN, Wilbur A; VEVE, Robert; HIRSCH, Fred R et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 3-14, issn 0093-7754, SUP4Article

Trastuzumab in the treatment of non-small cell lung cancerAZZOLI, Christopher G; KRUG, Lee M; MILLER, Vincent A et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 59-65, issn 0093-7754, SUP4Article

An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancerEDELMAN, Martin J.Seminars in oncology. 2005, Vol 32, Num 6, pp 3-8, issn 0093-7754, 6 p., SUP10Conference Paper

Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populationsJÄNNE, Pasi A.Seminars in oncology. 2005, Vol 32, Num 6, pp 9-15, issn 0093-7754, 7 p., SUP10Conference Paper

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancerRABEN, David; HELFRICH, Barbara A; CHAN, Dan et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 37-46, issn 0093-7754, SUP4Article

Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancersHERBST, Roy S; LANGER, Corey J.Seminars in oncology. 2002, Vol 29, Num 1, pp 27-36, issn 0093-7754, SUP4Article

Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatmentLYNCH, David H; YANG, Xiao-Dong.Seminars in oncology. 2002, Vol 29, Num 1, pp 47-50, issn 0093-7754, SUP4Article